Five Competitors Confirmed On Canadian Adalimumab
Amgen, Fresenius, Merck And Viatris Confirm Further Launches Of Humira Biosimilars
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
You may also be interested in...
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.
The Canadian Northwest Territories have become the fifth jurisdiction and first territorial government to implement a biosimilar switching policy.